Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,544.00
Bid: 12,544.00
Ask: 12,548.00
Change: 152.00 (1.23%)
Spread: 4.00 (0.032%)
Open: 12,468.00
High: 12,544.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-EU chief faces grilling over shaky COVID-19 vaccine strategy

Tue, 02nd Feb 2021 17:36

* EU under fire over slow vaccine rollout, border checks
issue

* Von der Leyen says Commission has been 'quick on its feet'

* Sees easing of supply problems as production ramps up
(Updates after meetings)

By Philip Blenkinsop

BRUSSELS, Feb 2 (Reuters) - EU lawmakers questioned chief
executive Ursula von der Leyen for hours on Tuesday over the
slow rollout and shortage of COVID-19 vaccines as she took
responsibility for an export control plan that angered Britain
and Ireland.

Three groups in the European Parliament on Tuesday evening
grilled Von der Leyen, a German who tweeted and appeared only on
German television in the first few days after the bloc imposed
curbs on vaccine exports on Friday.

Another parliament session was set for Wednesday morning,
and the groups want the EU president to appear before a full
session of parliament next week.

The COVID-19 vaccine crisis, which came to a head with the
EU export controls, followed news that AstraZeneca would
cut its supply of vaccines to the bloc until March by 60% due to
production problems.

Even with the addition of an extra 9 million doses that von
der Leyen announced on Sunday, the shortfall is at least 50%.

Questions still surround the Commission's decision -
swiftly reversed - to invoke Article 16 of the Brexit
agreement's Northern Ireland protocol. The move, part of the
EU's effort to boost vaccine supply for its member states, would
have set up border checks on the island of Ireland.

Von der Leyen accepted responsibility for Commission acts
and decisions, a person at one of Tuesday's meetings said.

The European Commission president repeated to lawmakers
arguments she made to newspapers as she sought to defuse
criticism over the slow start to COVID-19 vaccinations and
outrage over the border checks issue.

Asked by the Irish Times if she would apologise, von der
Leyen said she regretted that Article 16 was in a "provisional
version" of the decision, but said the EU executive had been
"quick on its feet" to find another solution.

Dacian Ciolos, president of the liberal Renew Europe group,
said mistakes could have grave consequences. "We have no margin
for error in this process. Not only does the credibility of the
EU and in particular the European Commission depend on it but
also the health and wellbeing of our citizens," he said in a
statement.

Sophie in 't Veld, a Dutch liberal lawmaker, said von der
Leyen was relying on too narrow a circle of advisers.

"She's made a couple of big fat mistakes. Article 16 was
one," she told Reuters, adding that her tendency to speak only
to German media was another problem.

EU countries have so far given first doses to about 3% of
their populations, compared with 9% for the United States and
14% for Britain, according to Our World in Data.

Von der Leyen said the EU had lagged rivals by three to four
weeks because of a more rigorous approvals process. Supply
problems should ease in the second quarter of 2021, but
increasing production remained a challenge.
(Reporting by Philip Blenkinsop; additional reporting by John
Chalmers
Editing by Gareth Jones, Angus MacSwan and Cynthia Osterman)

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.